Learn more about the BillionToOne, Inc. Investigation
Please Upload related files below
Add Transactions
Upload Your Stock Tickers
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
BillionToOne, Inc. Investigation Details
BillionToOne, Inc. shares fell on November 18, 2026, after short-seller Fuzzy Panda Research published a report alleging improper billing practices, undisclosed regulatory scrutiny, weaknesses in clinical claims, and potential reimbursement and compliance problems. The Fuzzy Panda Report also pointed to an allegedly previously undisclosed, ongoing investigation by the Tennessee's State Office Program of Integrity, which at one point purportedly determined a "credible allegation of fraud has been established." Just two weeks earlier, on November 4, 2026, Chief Financial Officer Ross Taylor raised full-year 2026 total revenue guidance to a range of $460 million to $470 million from $450 million to $465 million. In a Form 10-Q filed the same day, the Company reported $19.6 million of revenue from reprocessed prior-period claims and an approximate 112% increase in accounts receivable to $88.3 million, while representing that its team enabled a "more consistent, and accurate billing and appeal process." More than 90% of the Company's revenue came from third-party reimbursement. The investigation concerns whether BillionToOne, Inc. adequately disclosed its billing accuracy, reimbursement risks, and regulatory inquiries ahead of the November 18, 2026 short-seller report.